JTCS Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
John H. Lemmer, Jr.
William Stanford
Robert B. Karp
Glenn W. Laub
Hartzell V. Schaff
Constantine J. Tatooles
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lemmer, J. H.
Right arrow Articles by Rumberger, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lemmer, J. H., Jr.
Right arrow Articles by Rumberger, J. A.

J Thorac Cardiovasc Surg 1994;107:543-0553
© 1994 Mosby, Inc.

Cardiopulmonary Bypass, Myocardial Management, and Support Techniques

Aprotinin for coronary bypass operations: Efficacy, safety, and influence on early saphenous vein graft patencyA multicenter, randomized, double-blind, placebo-controlled study

John H. Lemmer, Jr., MDa (by invitation), William Stanford, MDb, Sharon L. Bonney, MDc (by invitation), Jerome F. Breen, MDd (by invitation), Eva V. Chomka, MDe (by invitation), W. Jay Eldredge, MDf (by invitation), William W. Holt, MDg (by invitation), Robert B. Karp, MDh, Glenn W. Laub, MDi (by invitation), Martin J. Lipton, MDj (by invitation), Hartzell V. Schaff, MDk, Constantine J. Tatooles, MDl, John A. Rumberger, PhD, MDm (by invitation)


Iowa City, Iowa, West Haven, Conn., Rochester, Minn., Chicago, Ill., and Browns Mills, N.J.

Supported by Miles Inc., West Haven, Conn.

Address for reprints: John H. Lemmer, Jr., MD, Northwest Surgical Associates, 226 NW Pettygrove, Portland, OR 97210.

Abstract

The purpose of this study was to evaluate the efficacy and safety of aprotinin in a U.S. population of patients undergoing coronary artery bypass grafting. Early vein graft patency rates were assessed by ultrafast computed tomography. A total of 216 patients at five centers were randomized to receive either high-dose aprotinin or placebo during the operation; 151 patients underwent primary operation, and 65 underwent repeat procedures. Total blood product exposures in the primary group were 2.2 per patient receiving aprotinin as compared with 5.7 per patient receiving placebo (p = 0.010). The repeat group had 0.3 exposures per patient receiving aprotinin as compared with 10.7 per patient receiving placebo (p = <0.001). Consistent reductions in the percent of patients requiring donor red blood cells and in the number of units of platelets, fresh frozen plasma, and cryoprecipitate required were associated with the use of aprotinin in both primary and repeat groups. Mortality was 5.6% in the aprotinin group and 3.7% in the placebo group (p = 0.517). In the primary group, clinical diagnoses of myocardial infarction were made in 8.9% of patients receiving aprotinin as compared with 5.6% of the patients receiving placebo (p = 0.435). In the repeat group, infarctions occurred in 10.3% of patients receiving aprotinin and 8.3% of patients receiving placebo (p = 1.000). Secondary analysis of electrocardiograms and available enzyme data showed no significant difference in infarction rates between the treatment groups. There was no difference in clinically significant renal dysfunction. The early vein graft patency rates were 92.0% in the aprotinin group and 95.1% in the placebo group (p = 0.248). In this study, aprotinin was effective in reducing bleeding and blood product transfusion rates, and its use was not associated with an increase in complications. An adverse effect on early vein graft patency rates was not demonstrated, but the number of grafts assessed was insufficient for absolute conclusions in this regard. (J THORAC CARDIOVASC SURG 1994;107:543-53)




This article has been cited by other articles:


Home page
 Ann. Thorac. Surg.Home page
D. L. Ngaage, A. R. Cale, M. E. Cowen, S. Griffin, and L. Guvendik
Aprotinin in primary cardiac surgery: operative outcome of propensity score-matched study.
Ann. Thorac. Surg., October 1, 2008; 86(4): 1195 - 1202.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
S. A. Olenchock Jr, P. H.U. Lee, T. Yehoshua, S. A. Murphy, J. Symes, and G. Tolis Jr
Impact of aprotinin on adverse clinical outcomes and mortality up to 12 years in a registry of 3,337 patients.
Ann. Thorac. Surg., August 1, 2008; 86(2): 560 - 566.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
J. Dunning, M. Versteegh, A. Fabbri, A. Pavie, P. Kolh, U. Lockowandt, S. A.M. Nashef, and on behalf of the EACTS Audit and Guidelines Commit
Guideline on antiplatelet and anticoagulation management in cardiac surgery.
Eur. J. Cardiothorac. Surg., July 1, 2008; 34(1): 73 - 92.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
T. M. Sundt
The demise of aprotinin: Our share of the blame.
J. Thorac. Cardiovasc. Surg., April 1, 2008; 135(4): 729 - 731.
[Full Text] [PDF]

Home page
 Anesth. Analg.Home page
M. P. Eaton
Antifibrinolytic Therapy in Surgery for Congenital Heart Disease
Anesth. Analg., April 1, 2008; 106(4): 1087 - 1100.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
S. Westaby
Aprotinin: Twenty-five years of claim and counterclaim
J. Thorac. Cardiovasc. Surg., March 1, 2008; 135(3): 487 - 491.
[Full Text] [PDF]

Home page
 Card Surg AdultHome page
L. Y. Lee, W. J. DeBois, K. H. Krieger, and O. W. Isom
Transfusion Therapy and Blood Conservation
Card. Surg. Adult, January 1, 2008; 3(2008): 415 - 430.
[Full Text]

Home page
 Card Surg AdultHome page
I. George and M. C. Oz
Myocardial Revascularization after Acute Myocardial Infarction
Card. Surg. Adult, January 1, 2008; 3(2008): 669 - 696.
[Full Text]

Home page
 Br J AnaesthHome page
P. J. Van der Linden, J.-F. Hardy, A. Daper, A. Trenchant, and S. G. De Hert
Cardiac surgery with cardiopulmonary bypass: does aprotinin affect outcome?
Br. J. Anaesth., November 1, 2007; 99(5): 646 - 652.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
J. R. Brown, N. J.O. Birkmeyer, and G. T. O'Connor
Meta-Analysis Comparing the Effectiveness and Adverse Outcomes of Antifibrinolytic Agents in Cardiac Surgery
Circulation, June 5, 2007; 115(22): 2801 - 2813.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
P. M. Mannucci and M. Levi
Prevention and Treatment of Major Blood Loss
N. Engl. J. Med., May 31, 2007; 356(22): 2301 - 2311.
[Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
The Society of Thoracic Surgeons Blood Conservatio, V. A. Ferraris, S. P. Ferraris, S. P. Saha, E. A. Hessel II, C. K. Haan, B. D. Royston, C. R. Bridges, R. S.D. Higgins, G. Despotis, et al.
Perioperative Blood Transfusion and Blood Conservation in Cardiac Surgery: The Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists Clinical Practice Guideline
Ann. Thorac. Surg., May 1, 2007; 83(5_Supplement): S27 - S86.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
D. T. Mangano, Y. Miao, A. Vuylsteke, I. C. Tudor, R. Juneja, D. Filipescu, A. Hoeft, M. L. Fontes, Z. Hillel, E. Ott, et al.
Mortality Associated With Aprotinin During 5 Years Following Coronary Artery Bypass Graft Surgery
JAMA, February 7, 2007; 297(5): 471 - 479.
[Abstract] [Full Text] [PDF]

Home page
 ICVTSHome page
A. Ronald and J. Dunning
Does use of aprotinin decrease the incidence of stroke and neurological complications in adult patients undergoing cardiac surgery?
Interactive CardioVascular and Thoracic Surgery, December 1, 2006; 5(6): 767 - 773.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
S. C. Body and C. D. Mazer
Pro: Aprotinin Has a Good Efficacy and Safety Profile Relative to Other Alternatives for Prevention of Bleeding in Cardiac Surgery
Anesth. Analg., December 1, 2006; 103(6): 1354 - 1359.
[Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
J. R. Cooper Jr, J. Abrams, O.H. Frazier, R. Radovancevic, B. Radovancevic, A. W. Bracey, M. J. Kindo, and I. D. Gregoric
Fatal pulmonary microthrombi during surgical therapy for end-stage heart failure: Possible association with antifibrinolytic therapy
J. Thorac. Cardiovasc. Surg., May 1, 2006; 131(5): 963 - 968.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
D. T. Mangano, I. C. Tudor, C. Dietzel, and the Multicenter Study of Perioperative Ischemia Re
The Risk Associated with Aprotinin in Cardiac Surgery
N. Engl. J. Med., January 26, 2006; 354(4): 353 - 365.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
L. Engles
Review and application of serine protease inhibition in coronary artery bypass graft surgery
Am. J. Health Syst. Pharm., September 15, 2005; 62(18_Supplement_4): S9 - S14.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
J. H. Levy
Overview of clinical efficacy and safety of pharmacologic strategies for blood conservation
Am. J. Health Syst. Pharm., September 15, 2005; 62(18_Supplement_4): S15 - S19.
[Abstract] [Full Text] [PDF]

Home page
 Clin TrialsHome page
D. Fergusson, K. C. Glass, B. Hutton, and S. Shapiro
Randomized controlled trials of aprotinin in cardiac surgery: could clinical equipoise have stopped the bleeding?
Clinical Trials, June 1, 2005; 2(3): 218 - 232.
[Abstract] [PDF]

Home page
 SEMIN CARDIOTHORAC VASC ANESTHHome page
A. Shander, D. Moskowitz, and T. S. Rijhwani
The Safety and Efficacy of "Bloodless" Cardiac Surgery
Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 2005; 9(1): 53 - 63.
[Abstract] [PDF]

Home page
 Br J AnaesthHome page
A. M. Mahdy and N. R. Webster
Perioperative systemic haemostatic agents
Br. J. Anaesth., December 1, 2004; 93(6): 842 - 858.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
A. Sedrakyan, T. Treasure, and J. A. Elefteriades
Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: A systematic review and meta-analysis of randomized clinical trials
J. Thorac. Cardiovasc. Surg., September 1, 2004; 128(3): 442 - 448.
[Abstract] [Full Text] [PDF]

Home page
 Br J AnaesthHome page
T. Bombeli and D. R. Spahn
Updates in perioperative coagulation: physiology and management of thromboembolism and haemorrhage
Br. J. Anaesth., August 1, 2004; 93(2): 275 - 287.
[Abstract] [Full Text] [PDF]

Home page
 ICVTSHome page
M. Kalkat, A. Levine, and J. Dunning
Does use of aprotinin in coronary artery bypass graft surgery affect graft patency?
Interactive CardioVascular and Thoracic Surgery, March 1, 2004; 3(1): 124 - 128.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
P. K. Smith, S. K. Datta, L. H. Muhlbaier, G. Samsa, A. Nadel, and J. Lipscomb
Cost analysis of aprotinin for coronary artery bypass patients: analysis of the randomized trials
Ann. Thorac. Surg., February 1, 2004; 77(2): 635 - 642.
[Abstract] [Full Text] [PDF]

Home page
 Canadian J. AnesthesiaHome page
S. R. Williams, A. Y. Denault, M. Pellerin, and R. Martineau
Vasopressin for treatment of shock following aprotinin administration: [Traitement a la vasopressine pour un choc suivant l'administration d'aprotinine]
Can J Anesth, February 1, 2004; 51(2): 169 - 172.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
D. P. Taggart, V. Djapardy, M. Naik, and A. Davies
A randomized trial of aprotinin (Trasylol) on blood loss, blood product requirement, and myocardial injury in total arterial grafting
J. Thorac. Cardiovasc. Surg., October 1, 2003; 126(4): 1087 - 1094.
[Abstract] [Full Text] [PDF]

Home page
 SEMIN CARDIOTHORAC VASC ANESTHHome page
J. M. Karski and J. T. Balatbat
Blood Conservation Strategies in Cardiac Surgery
Seminars in Cardiothoracic and Vascular Anesthesia, June 1, 2003; 7(2): 175 - 188.
[Abstract] [PDF]

Home page
 Card Surg AdultHome page
L. Y. Lee, W. J. DeBois, K. H. Krieger, and O. W. Isom
Transfusion Therapy and Blood Conservation
Card. Surg. Adult, January 1, 2003; 2(2003): 389 - 400.
[Full Text]

Home page
 Card Surg AdultHome page
D. C. Lee, W. Ting, and M. C. Oz
Myocardial Revascularization after Acute Myocardial Infarction
Card. Surg. Adult, January 1, 2003; 2(2003): 639 - 658.
[Full Text]

Home page
 Ann. Thorac. Surg.Home page
J. M. Murkin, J. Maurer, and S. Niemcryk
Full dose aprotinin administration is associated with a significant decrease in perioperative stroke in patients undergoing elective cardiac surgery: a meta-analysis
Ann. Thorac. Surg., January 1, 2002; 73(1): S374 - 374.
[Full Text] [PDF]

Home page
 PerfusionHome page
M D Linden, M Schneider, and W N Erber
Factor VLEIDEN and cardiopulmonary bypass: investigation of haemostatic parameters and the effect of aprotinin using an ex vivo model
Perfusion, December 1, 2001; 16(6): 476 - 484.
[Abstract] [PDF]

Home page
 Ann. Thorac. Surg.Home page
G. J. Despotis, M. S. Avidan, and C. W. Hogue Jr
Mechanisms and attenuation of hemostatic activation during extracorporeal circulation
Ann. Thorac. Surg., November 1, 2001; 72(5): S1821 - 1831.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
J. M. Murkin
Attenuation of neurologic injury during cardiac surgery
Ann. Thorac. Surg., November 1, 2001; 72(5): S1838 - 1844.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
S. Westaby, T. Katsumata, and G. Vaccari
Aortic root replacement with coronary button re-implantation: low risk and predictable outcome
Eur. J. Cardiothorac. Surg., March 1, 2000; 17(3): 259 - 265.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
M. De Bonis, F. Cavaliere, F. Alessandrini, E. Lapenna, F. Santarelli, U. Moscato, R. Schiavello, and G. F. Possati
TOPICAL USE OF TRANEXAMIC ACID IN CORONARY ARTERY BYPASS OPERATIONS: A DOUBLE-BLIND, PROSPECTIVE, RANDOMIZED, PLACEBO-CONTROLLED STUDY
J. Thorac. Cardiovasc. Surg., March 1, 2000; 119(3): 575 - 580.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
B. P. Bidstrup, B. J. Hunt, S. Sheikh, R. N. Parratt, J. M. Bidstrup, and R. N. Sapsford
Amelioration of the bleeding tendency of preoperative aspirin after aortocoronary bypass grafting
Ann. Thorac. Surg., February 1, 2000; 69(2): 541 - 547.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
J. C. K. Fitch, S. Rollins, L. Matis, B. Alford, S. Aranki, C. D. Collard, M. Dewar, J. Elefteriades, R. Hines, G. Kopf, et al.
Pharmacology and Biological Efficacy of a Recombinant, Humanized, Single-Chain Antibody C5 Complement Inhibitor in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardiopulmonary Bypass
Circulation, December 21, 1999; 100(25): 2499 - 2506.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
P. B. Berger, E. L. Alderman, A. Nadel, and H. V. Schaff
Frequency of Early Occlusion and Stenosis in a Left Internal Mammary Artery to Left Anterior Descending Artery Bypass Graft After Surgery Through a Median Sternotomy on Conventional Bypass : Benchmark for Minimally Invasive Direct Coronary Artery Bypass
Circulation, December 7, 1999; 100(23): 2353 - 2358.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
M. J. Ray, K. F. Brown, C. A. Burrows, and M. F. O’Brien
Economic evaluation of high-dose and low-dose aprotinin therapy during cardiopulmonary bypass
Ann. Thorac. Surg., September 1, 1999; 68(3): 940 - 945.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
J. J. Munoz, N. J. O. Birkmeyer, J. D. Birkmeyer, G. T. O'Connor, and L. J. Dacey
Is {epsilon}-Aminocaproic Acid as Effective as Aprotinin in Reducing Bleeding With Cardiac Surgery? : A Meta-Analysis
Circulation, January 12, 1999; 99(1): 81 - 89.
[Abstract] [Full Text] [PDF]

Home page
 PerfusionHome page
J. A. Hyde, J. A Chinn, and T. R Graham
Platelets and cardiopulmonary bypass
Perfusion, December 1, 1998; 13(6): 389 - 407.
[PDF]

Home page
 Ann. Thorac. Surg.Home page
J. B. Rich
The efficacy and safety of aprotinin use in cardiac surgery
Ann. Thorac. Surg., November 1, 1998; 66(90050): S6 - 11.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
P. M. Mannucci
Hemostatic Drugs
N. Engl. J. Med., July 23, 1998; 339(4): 245 - 253.
[Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
B. Eberle, E. Mayer, G. Hafner, J. Heinermann, M. Dahm, W. Prellwitz, W. Dick, and H. Oelert
High-Dose {epsilon}-Aminocaproic Acid Versus Aprotinin: Antifibrinolytic Efficacy in First-Time Coronary Operations
Ann. Thorac. Surg., March 1, 1998; 65(3): 667 - 673.
[Abstract] [Full Text] [PDF]

Home page
 CLIN APPL THROMB HEMOSTHome page
R. Pifarre
Use of Aprotinin in the Control of Bleeding During Cardiopulmonary Bypass Surgery: Current Status
Clinical and Applied Thrombosis/Hemostasis, January 1, 1998; 4(1): 2 - 6.
[Abstract] [PDF]

Home page
 Ann. Thorac. Surg.Home page
W. Dietrich, K. Schopf, M. Spannagl, M. Jochum, S. L. Braun, and H. Meisner
Influence of High- and Low-Dose Aprotinin on Activation of Hemostasis in Open Heart Operations
Ann. Thorac. Surg., January 1, 1998; 65(1): 70 - 77.
[Abstract] [Full Text] [PDF]

Home page
 SEMIN CARDIOTHORAC VASC ANESTHHome page
B. P. Bidstrup
Coronary Artery Bypass Graft Patency
Seminars in Cardiothoracic and Vascular Anesthesia, November 1, 1997; 1(4): 282 - 287.
[Abstract] [PDF]

Home page
 SEMIN CARDIOTHORAC VASC ANESTHHome page
S. Westaby
Aprotinin Fifteen Years Later
Seminars in Cardiothoracic and Vascular Anesthesia, November 1, 1997; 1(4): 366 - 375.
[Abstract] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
J. Weipert, H. Meisner, M. Jochum, and W. Dietrich
LONG-TERM FOLLOW-UP OF APROTININ-SPECIFIC IMMUNOGLOBULIN G ANTIBODIES AFTER CARDIAC OPERATIONS
J. Thorac. Cardiovasc. Surg., October 1, 1997; 114(4): 676 - 678.
[Full Text]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
N. Hayashida, T. Isomura, T. Sato, H. Maruyama, K. Kosuga, and S. Aoyagi
EFFECTS OF MINIMAL-DOSE APROTININ ON CORONARY ARTERY BYPASS GRAFTING
J. Thorac. Cardiovasc. Surg., August 1, 1997; 114(2): 261 - 269.
[Abstract] [Full Text]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
T. J. Vander Salm
Use of epsilon-aminocaproic acid to reduce bleeding
J. Thorac. Cardiovasc. Surg., June 1, 1997; 113(6): 1126 - 1127.
[Full Text]

Home page
 Ann. Thorac. Surg.Home page
P. K. Smith and L. H. Muhlbaier
Aprotinin: Safe and Effective Only With the Full-Dose Regimen
Ann. Thorac. Surg., December 1, 1996; 62(6): 1575 - 1577.
[Full Text]

Home page
 Ann. Thorac. Surg.Home page
J. H. Lemmer Jr, E. W. Dilling, J. R. Morton, J. B. Rich, F. Robicsek, D. L. Bricker, C. B. Hantler, J. G. Copeland III, J. L. Ochsner, P. O. Daily, et al.
Aprotinin for Primary Coronary Artery Bypass Grafting: A Multicenter Trial of Three Dose Regimens
Ann. Thorac. Surg., December 1, 1996; 62(6): 1659 - 1668.
[Abstract] [Full Text]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
J. H. Lemmer Jr., M. T. Metzdorff, A. H. Krause, J. E. Okies, T. A. Molloy, J. G. Hill, W. B. Long, T. R. Winkler, and U. S. Page
APROTININ USE IN PATIENTS WITH DIALYSIS-DEPENDENT RENAL FAILURE UNDERGOING CARDIAC OPERATIONS
J. Thorac. Cardiovasc. Surg., July 1, 1996; 112(1): 192 - 194.
[Full Text]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
M. J. Moulton, L. L. Creswell, M. E. Mackey, J. L. Cox, and M. Rosenbloom
REEXPLORATION FOR BLEEDING IS A RISK FACTOR FOR ADVERSE OUTCOMES AFTER CARDIAC OPERATIONS
J. Thorac. Cardiovasc. Surg., May 1, 1996; 111(5): 1037 - 1046.
[Abstract] [Full Text]

Home page
 CLIN APPL THROMB HEMOSTHome page
M. S. Irani
Antithrombin Concentrates in Heparin-Resistant Cardiopulmonary Bypass Patients
Clinical and Applied Thrombosis/Hemostasis, April 1, 1996; 2(2): 103 - 106.
[Abstract] [PDF]

Home page
 Ann. Thorac. Surg.Home page
D. Katsaros, M. Petricevic, N. J. Snow, D. D. Woodhall, and R. Van Bergen
Tranexamic Acid Reduces Postbypass Blood Use: A Double-Blinded, Prospective, Randomized Study of 210 Patients
Ann. Thorac. Surg., April 1, 1996; 61(4): 1131 - 1135.
[Abstract] [Full Text]

Home page